An overview of the Chinese legal regime regarding expanded access to investigational drugs and medical devices. The Note sets out the requirements and responsibilities in relation to the expanded access programme (EAP) under Chinese laws and regulations. It briefly discusses the Food and Drug Administration's expanded access rules and compares the US approach with the developing Chinese regime. The Note also discusses how the Chinese expanded access regime may work in public health emergencies.